CLDX - Celldex Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908-200-7500
http://www.celldex.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees133

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony S. MarucciFounder, Pres, CEO & Director916.54kN/A1962
Dr. Tibor KelerFounder, Chief Scientific Officer & Exec. VP578.63kN/A1959
Mr. Sam MartinSr. VP, CFO, Sec. & Treasurer449.99kN/A1971
Ms. Elizabeth CrowleyChief Product Devel. Officer & Sr. VP454.87kN/A1972
Dr. Margo Heath-Chiozzi M.D.Sr. VP of Regulatory Affairs482.83kN/A1957
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, currently being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in multiple types of solid tumors and B cell lymphomas; CDX-3379, a human monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-301, a dendritic cell growth factor; and Varlilumab, an immune modulating antibody targeting CD27 designed to enhance a patient's immune response. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.